GlassScriptPhysician profile
Debra Kay Cooper
NPI 1144261249
$345.35
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $28.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.21 | 2019 | |
| Lilly USA, LLC | $46.31 | 2019 | |
| Glaxosmithkline, LLC. | $43.55 | 2019 | |
| Novo Nordisk INC | $35.47 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $35.15 | 2019 | |
| Neos Therapeutics, LP | $30.50 | 2019 | |
| Amarin Pharma, INC. | $23.76 | 2019 | |
| Boston Scientific Corporation | $23.04 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.55 | 2020 | |
| Astellas Pharma US INC | $14.13 | 2019 | |
| Amgen INC. | $11.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.74 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.